Recent Finacing
Recent Raise
OncoSynergy, a UCSF spinout developing Resistance Mechanism Inhibitors for oncology, advances lead program OS2966 (FDA orphan-designated for glioblastoma), pursuing preclinical combination studies and clinical trials via Infuseon alliance.
Focus Areas
Recent Investors
Funding round
Investors
